GH Secretagogue Research Peptides: A Structural Overview

Key takeaways

• The compounds catalogued together as 'GH secretagogues' are not one chemical family; they split into at least two distinct peptide classes plus one non-peptide small molecule.
• Class one is the GHRH analogs (sermorelin, CJC-1295, tesamorelin) modified versions of growth-hormone-releasing hormone built on the GHRH(1-29) or GHRH(1-44) backbone.
• Class two is the ghrelin-receptor (GHS-R) agonists, the synthetic growth-hormone-releasing peptides such as ipamorelin, GHRP-2, GHRP-6, and hexarelin small synthetic chains unrelated to the GHRH sequence.
• MK-677 (ibutamoren) is grouped functionally alongside these but is a non-peptide small molecule, not a peptide at all so it belongs to neither peptide class.
• Ascend Bio Labs supplies these research peptides with a public, per-batch COA keyed to the batch ID on each vial, independent third-party HPLC for purity and LC-MS for identity, all US-domestic.

Walk down the 'GH secretagogue' shelf of any research-peptide catalogue and you will find a dozen names filed next to one another sermorelin, CJC-1295, tesamorelin, ipamorelin, GHRP-2, GHRP-6, hexarelin, MK-677 as if they were variations on a single theme. Structurally they are not. The label 'secretagogue' describes a functional grouping (compounds studied for their action on the growth-hormone axis), and lumping them by function hides the fact that they belong to fundamentally different chemical classes with different backbones, different sequence lengths, and in one case no peptide bonds at all. This overview re-sorts the shelf by structure, so the catalogue makes chemical sense rather than just functional sense.

This is strictly a structural and classification piece. It covers what kind of molecule each class contains, the backbone it is built on, the approximate sequence length and molecular-weight range, and how to tell the classes apart on a certificate of analysis. It does not address what any of these compounds do in any organism that is outside the scope of a research-reagent reference, and outcome framing on research chemicals would be both inaccurate and inappropriate. Read this as a map of the chemistry, not a claim about effects.

Why 'secretagogue' is a functional label, not a structural one

The word secretagogue groups molecules by what they are studied in relation to the secretion of growth hormone rather than by what they are made of. That is a perfectly normal way to organize a research catalogue, because it is how buyers search. But it is the wrong axis if you want to understand the chemistry, because two compounds can sit under the same functional heading while having nothing structural in common: one might be a 44-residue modified natural hormone and the next a 5-residue wholly synthetic chain.

Sorting by structure instead reveals a clean split. On one side are the GHRH analogs molecules built on the sequence of growth-hormone-releasing hormone itself, modified for stability. On the other side are the ghrelin-receptor agonists, also called growth-hormone-releasing peptides (GHRPs), which are short synthetic chains that bear no resemblance to the GHRH sequence and act at a different receptor. Sitting outside both peptide classes is MK-677, a non-peptide small molecule that is catalogued alongside the peptides purely because of the receptor family it is studied against.

Knowing which class a compound belongs to is what lets you sanity-check its certificate of analysis. A GHRH(1-44) analog should report a mass near 5 kDa; a pentapeptide GHRP should report a mass under 1 kDa; and a non-peptide will not even have a residue sequence to report. If a COA's stated molecular weight is wildly inconsistent with the class the product name implies, that is a signal worth investigating. For how those certificates are read in general, see How to Read a Peptide COA.

• 'Secretagogue' groups compounds by function (the GH axis), not by chemical structure.
• By structure the group splits into GHRH analogs and ghrelin-receptor (GHS-R) agonists.
• MK-677 is filed here functionally but is a non-peptide small molecule, in neither peptide class.
• Class predicts the expected molecular-weight range, a useful COA cross-check.

Class 1 — GHRH analogs: modified versions of a natural hormone

The first structural class is the GHRH analogs. Native human growth-hormone-releasing hormone is a 44-residue peptide, conventionally written GHRH(1-44), and its first 29 residues GHRH(1-29) carry the segment most associated with receptor binding. Every compound in this class is built on one of those two backbones (the full 1-44 chain or the truncated 1-29 fragment) and then modified at the termini for stability. They are analogs of a real human sequence, not invented-from-scratch chains.

Sermorelin is the GHRH(1-29) fragment, a 29-residue analog and the shortest member of the class. CJC-1295 is also built on the GHRH(1-29) backbone, modified with stabilizing residue substitutions and, in its 'with DAC' form, a Drug Affinity Complex group that lengthens its circulating presence; the structural difference between the DAC and no-DAC versions is the subject of What Is CJC-1295? GHRH Analog Structure, With and Without DAC. Tesamorelin is the heavyweight: it keeps the full 44-residue GHRH(1-44) backbone and adds an N-terminal trans-3-hexenoyl cap, putting it near 5.1 kDa the full sequence and molecular weight are covered in What Is Tesamorelin? GHRH Analog Sequence and Molecular Weight.

What unites the class structurally is the GHRH backbone and the analog-of-a-natural-sequence design. What varies is the backbone length (1-29 vs 1-44) and the specific stabilizing modification, which is why their molecular weights span a wide range from roughly 3 kDa for a GHRH(1-29) analog up to about 5.1 kDa for tesamorelin. On a COA, members of this class will report a long residue sequence and a multi-kilodalton mass.

• Backbone: native human GHRH, either the 1-29 fragment or the full 1-44 chain.
• Sermorelin = GHRH(1-29) analog, 29 residues; the shortest in the class.
• CJC-1295 = modified GHRH(1-29) analog; a DAC variant extends its presence.
• Tesamorelin = full GHRH(1-44) analog with N-terminal hexenoyl cap, ~5.1 kDa.
• Class signature on a COA: long sequence, multi-kilodalton molecular weight.

Class 2 — Ghrelin-receptor agonists: short synthetic peptides (GHRPs)

The second structural class is the ghrelin-receptor agonists, more commonly catalogued as growth-hormone-releasing peptides (GHRPs). These are short, wholly synthetic peptide chains that are unrelated to the GHRH sequence; they act at the growth-hormone secretagogue receptor (GHS-R), the same receptor family that the natural hormone ghrelin binds. That different receptor target is the structural-functional dividing line between this class and the GHRH analogs above.

These chains are small. Ipamorelin is a five-residue pentapeptide near 700 g/mol the smallest commonly catalogued member and its specs are detailed in What Is Ipamorelin? Pentapeptide GH Secretagogue Specs. GHRP-2 and GHRP-6 are likewise short synthetic peptides (six residues for GHRP-6, a closely related sequence for GHRP-2), and hexarelin is another short synthetic GHRP. None of these is built on a natural human sequence the way the GHRH analogs are; they were designed as compact synthetic agonists, often incorporating non-standard or D-amino-acid residues that improve stability and are part of what an identity check confirms.

Because these chains are short, their molecular weights cluster well under 1 kilodalton, in clear contrast to the multi-kilodalton GHRH analogs. That single fact (sub-1 kDa, sequence of roughly 5-6 residues, often containing modified residues) is the structural fingerprint of the class. If a product sold as a GHRP reports a mass of several thousand daltons on its COA, the name and the chemistry disagree, and that warrants a closer look before the material is trusted.

• Receptor class: ghrelin / growth-hormone-secretagogue receptor (GHS-R), not the GHRH receptor.
• Wholly synthetic short chains, not analogs of a natural human sequence.
• Ipamorelin = 5-residue pentapeptide (~700 g/mol); GHRP-6 = 6 residues; GHRP-2 and hexarelin closely related short GHRPs.
• Often contain non-standard or D-amino-acid residues for stability.
• Class signature on a COA: short sequence, sub-1 kDa molecular weight.

The outlier — MK-677 (ibutamoren) is not a peptide at all

MK-677, also called ibutamoren, is routinely shelved next to the peptides in this category, and that placement is purely functional it is studied against the same GHS-R receptor family as the GHRP class. Structurally, though, it is the odd one out: MK-677 is a non-peptide small molecule. It has no amino-acid residues, no peptide bonds, and therefore no 'sequence' in the sense the other compounds do. Its structural profile is the subject of What Is MK-677 (Ibutamoren)? Non-Peptide GH Secretagogue Profile.

This matters for handling and for reading a certificate. A peptide COA confirms a residue sequence and a peptide mass; a small-molecule certificate confirms a defined chemical structure and its formula mass, and the identity-confirmation tooling is framed around a single small molecule rather than a polymer of residues. MK-677 is also frequently supplied for oral-research formats in some catalogues rather than as a lyophilized injectable-research vial, which again sets it apart from the peptide members.

The practical takeaway is to not let shelf placement imply chemical kinship. MK-677 shares a functional category with the GHRPs and GHRH analogs, but it is a separate kind of molecule entirely. Treating it as 'just another peptide in the secretagogue group' would lead you to expect the wrong COA fields and the wrong storage form.

• MK-677 (ibutamoren) is a non-peptide small molecule, not a peptide.
• No residues, no peptide bonds, no sequence to report on a COA.
• Filed with the peptides only because of the shared GHS-R functional category.
• Its certificate confirms a small-molecule structure and formula mass, not a sequence.

Side-by-side: the secretagogue catalogue sorted by structural class

Pulling the classes together makes the structural logic visible at a glance. The table below sorts the commonly catalogued GH-secretagogue research compounds by class, with the approximate sequence length and molecular-weight range that each class predicts. The figures are rounded and meant for structural orientation; the authoritative numbers for any given vial come from that batch's certificate of analysis, not from a category table.

Use the molecular-weight column as a quick cross-check. A compound's class should match the mass its product name implies a GHRH(1-44) analog near 5 kDa, a pentapeptide GHRP under 1 kDa, a non-peptide reported by formula mass. When the catalogue label and the certificate disagree, trust the certificate and ask the vendor.

What stays constant across every class: batch-level verification

Whatever class a compound belongs to GHRH analog, ghrelin-receptor agonist, or non-peptide small molecule the way you confirm you received the molecule the label names is the same: a certificate of analysis tied to the specific batch, with purity measured by HPLC and identity confirmed by mass spectrometry. The class only changes what the certificate should say (a long sequence and high mass for a GHRH analog, a short sequence and low mass for a GHRP, a formula mass for MK-677). The need for the certificate is constant. For the distinction between the two analyses, see HPLC vs LC-MS Peptide Testing: What Each Measures.

This is where the structural map and supplier verification meet. Ascend Bio Labs supplies these research compounds with a public, per-batch certificate of analysis keyed to the unique batch ID printed on each vial, with independent third-party HPLC for purity and LC-MS for molecular identity. Synthesis, testing, storage, and shipping are all US-domestic, with insulated and tracked transit, so the vial that arrives is the one its certificate describes. The class of the molecule tells you what the COA should report; the per-batch COA tells you whether the specific vial in your hand actually matches.

A few peer suppliers in the research-peptide space also state batch-level testing and US operations on their sites; what varies is exactly what is published and where. Several state HPLC plus mass-spectrometry testing and a 99%-class purity specification (for example BioLongevity Labs, Protide Health, Paramount Peptides, and Limitless Life Nootropics, per their own sites), while a smaller number state a publicly searchable batch-ID COA lookup specifically. For others, COA publication or third-party testing details are not publicly listed on the pages reviewed verify directly with the vendor. The point of this section is not to rank vendors but to anchor the structural map to a verification step you can actually perform.

• Every class is verified the same way: per-batch COA, HPLC for purity, mass spec for identity.
• Class determines what the COA should report; it does not remove the need for one.
• Ascend Bio Labs: public per-batch COA by batch ID, third-party HPLC + LC-MS, US-domestic.
• Where a peer's COA or testing details are not publicly listed, verify directly with that vendor.

Related research notes

• What Is CJC-1295? GHRH Analog Structure, With and Without DAC
• What Is Ipamorelin? Pentapeptide GH Secretagogue Specs
• What Is Tesamorelin? GHRH Analog Sequence and Molecular Weight
• What Is MK-677 (Ibutamoren)? Non-Peptide GH Secretagogue Profile